Literature DB >> 32632012

The implications of silent transmission for the control of COVID-19 outbreaks.

Seyed M Moghadas1, Meagan C Fitzpatrick2,3, Pratha Sah2, Abhishek Pandey2, Affan Shoukat2, Burton H Singer4, Alison P Galvani5.   

Abstract

Since the emergence of coronavirus disease 2019 (COVID-19), unprecedented movement restrictions and social distancing measures have been implemented worldwide. The socioeconomic repercussions have fueled calls to lift these measures. In the absence of population-wide restrictions, isolation of infected individuals is key to curtailing transmission. However, the effectiveness of symptom-based isolation in preventing a resurgence depends on the extent of presymptomatic and asymptomatic transmission. We evaluate the contribution of presymptomatic and asymptomatic transmission based on recent individual-level data regarding infectiousness prior to symptom onset and the asymptomatic proportion among all infections. We found that the majority of incidences may be attributable to silent transmission from a combination of the presymptomatic stage and asymptomatic infections. Consequently, even if all symptomatic cases are isolated, a vast outbreak may nonetheless unfold. We further quantified the effect of isolating silent infections in addition to symptomatic cases, finding that over one-third of silent infections must be isolated to suppress a future outbreak below 1% of the population. Our results indicate that symptom-based isolation must be supplemented by rapid contact tracing and testing that identifies asymptomatic and presymptomatic cases, in order to safely lift current restrictions and minimize the risk of resurgence.
Copyright © 2020 the Author(s). Published by PNAS.

Entities:  

Keywords:  COVID-19; case isolation; contact tracing

Mesh:

Year:  2020        PMID: 32632012      PMCID: PMC7395516          DOI: 10.1073/pnas.2008373117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


Many countries, including the United States, are struggling to control coronavirus disease 2019 (COVID-19) outbreaks. Understanding how silent infections that are in the presymptomatic phase or asymptomatic contribute to transmission will be fundamental to the success of postlockdown control strategies. The effectiveness of symptom-based interventions depends on the fraction of infections that are asymptomatic, the infectiousness of those asymptomatic cases, and the duration and infectiousness of the presymptomatic phase. Empirical studies have indicated that individuals may be most infectious during the presymptomatic phase (1), an unusual characteristic for a respiratory infection. To quantify the population-level contribution of silent transmission to COVID-19 spread, we extended our previous model (2, 3) to include asymptomatic infections and the presymptomatic stage, parameterized with data regarding the trajectory of symptom onset and the proportion of secondary cases generated in each stage of infection (1, 4). As empirical studies indicate that asymptomatic infections account for 17.9 to 30.8% of all infections (5, 6), for both of these values, we quantified the proportion of the attack rate attributable to transmission during presymptomatic, asymptomatic, and symptomatic stages. Furthermore, this quantification was combined with a series of scenario analyses to identify the level of isolation required for symptomatic or silently infected individuals, to suppress the attack rate below 1%. Our results highlight the role of silent transmission as the primary driver of COVID-19 outbreaks and underscore the need for mitigation strategies, such as contact tracing, that detect and isolate infectious individuals prior to the onset of symptoms.

Results

Translating clinical data on infectiousness and symptoms (1) to population-level epidemiological impact, our results indicate that the majority of transmission is attributable to people who are not exhibiting symptoms, either because they are still in the presymptomatic stage or the infection is asymptomatic (Fig. 1). Specifically, if 17.9% of infections are asymptomatic (5), we found that the presymptomatic stage and asymptomatic infections account for 48% and 3.4% of transmission, respectively (Fig. 1). Considering a greater asymptomatic proportion of 30.8% reported in another empirical study (6), the presymptomatic phase and asymptomatic infections account for 47% and 6.6% of transmission, respectively (Fig. 1). Consequently, even immediate isolation of all symptomatic cases is insufficient to achieve control (Fig. 1). Specifically, mean attack rates remain above 25% of the population when 17.9% of infections are asymptomatic and above 28% when 30.8% of infectious are asymptomatic.
Fig. 1.

Attack rates when the proportion of infections that are asymptomatic is (A) 17.9% and (B) 30.8%, for scenarios of case isolation including none (yellow), all severe cases (red), and all symptomatic cases (blue). Bars indicate the proportion of attack rate attributable to transmission in different stages of infections. (C) Attack rate when a percentage of silent (i.e., presymptomatic and asymptomatic) infections are detected and isolated in addition to immediate isolation of both mild and severe symptomatic cases.

Attack rates when the proportion of infections that are asymptomatic is (A) 17.9% and (B) 30.8%, for scenarios of case isolation including none (yellow), all severe cases (red), and all symptomatic cases (blue). Bars indicate the proportion of attack rate attributable to transmission in different stages of infections. (C) Attack rate when a percentage of silent (i.e., presymptomatic and asymptomatic) infections are detected and isolated in addition to immediate isolation of both mild and severe symptomatic cases. Given the inadequacy of symptom-based isolation to control COVID-19 outbreaks, we considered the synergistic impact of isolation for presymptomatic and asymptomatic infections. Combined with case isolation, our results indicate that 33% and 42% detection and isolation of silent infections would be needed to suppress the attack rate below 1%, for asymptomatic proportions of 17.9% and 30.8%, respectively (Fig. 1).

Discussion

Our results indicate that silent disease transmission during the presymptomatic and asymptomatic stages are responsible for more than 50% of the overall attack rate in COVID-19 outbreaks. Furthermore, such silent transmission alone can sustain outbreaks even if all symptomatic cases are immediately isolated. The results corroborate recent contact tracing studies indicating a substantial role of presymptomatic transmission among 243 COVID-19 cases in Singapore (7) and 468 COVID-19 cases in China (8). Our findings highlight the urgent need to scale up testing of suspected cases without symptoms as noted in revised guidelines by Centers for Disease Control and Prevention (9). Furthermore, symptom-based surveillance must be supplemented by rapid contact-based surveillance that can identify exposed individuals prior to their infectious period (10). Specifically, our estimation for isolation of silently infected individuals is a lower bound, as inevitable imperfections in isolation of symptomatic cases translates to a greater need to prevent silent transmission. Delays in contact tracing increase the risk of onward transmission, especially since those without symptoms are generally unaware of their infection risk to others, and therefore are less likely to curtail social interactions. Therefore, our estimates of the realized transmission from a silently infected individual, and their relative contribution to transmission under status quo, is likely to be conservative. These dangers are particularly salient in the context of deliberations about lifting social distancing restrictions. Complicating future surveillance and control efforts of COVID-19 is the possibility that the seasonal drivers of influenza might comparably intensify transmission of COVID-19, such that a resurgence of COVID-19 would coincide with the next influenza season in the Northern Hemisphere. Similarities in symptoms between the two diseases may further erode the effectiveness of measures that rely on symptoms. As plans are being implemented for lifting mitigation measures, the benefits of contact-based surveillance should be evaluated to ensure adequate resources are deployed to suppress ongoing outbreaks, prevent rebound, and minimize the impact of future COVID-19 waves.

Materials and Methods

We extended our agent-based COVID-19 transmission model (3) to include the presymptomatic phase and asymptomatic infections based on recent empirical evidence (1, 4). Each individual had an associated epidemiological status: susceptible, infected and incubating, presymptomatic, asymptomatic, symptomatic with either mild or severe illness, recovered, or dead. The daily number of contacts for each individual was sampled from an age-specific negative-binomial distribution based on an empirically determined contact matrix (11). In the absence of case isolation, each individual has 10.21 (SD: 7.65), 16.79 (SD: 11.72), 13.79 (SD: 10.50), 11.26 (SD: 9.59), and 8.00 (SD: 6.96) daily contacts in age groups 0 y to 4 y, 5 y to 19 y, 20 y to 49 y, 50 y to 64 y, and 65+ y, respectively. Transmission was implemented probabilistically for contacts between susceptible and infectious individuals in the presymptomatic, asymptomatic, or symptomatic stages (Table 1). A proportion of infected individuals remained asymptomatic through recovery (5, 6), with an average infectious period of 5.0 d (12). The remaining proportion of infected individuals developed symptoms after an average incubation period of 5.2 d, which was sampled from a log-normal distribution (13). For symptomatic cases, the incubation period included a highly infectious presymptomatic stage prior to the onset of symptoms (1). The duration of the presymptomatic stage was sampled from a Gamma distribution with a mean of 2.3 d (1). Infectious period for symptomatic cases after the onset of symptoms was sampled from a Gamma distribution with a mean of 3.2 d (14). Among symptomatic cases, we applied an age-dependent probability of mild or severe illness (2, 3). Taking into account that infectiousness is estimated to peak 0.7 d before symptom onset (1), we calculated the transmissibility within each phase relative to the presymptomatic phase. These relative transmissibilities were estimated as 11%, 44%, and 89%, calculated using R0 components of asymptomatic, mild symptomatic, and severe symptomatic phases (4). To account for empirical uncertainty in these parameters, we sampled these values from a uniform distribution in the ranges of 0.05 to 0.16, 0.39 to 0.49, and 0.84 to 0.94, for asymptomatic, mild symptomatic, and severe symptomatic, respectively.
Table 1.

Model parameters and their distributions

DescriptionAge groupSource
0 y to 4 y5 y to 19 y20 y to 49 y50 y to 64 y≥65 y
Transmission probability per contact during presymptomatic stage0.0575, 0.06980.0575, 0.06980.0575, 0.06980.0575, 0.06980.0575, 0.0698Calibrated to R0 = 2.5
Incubation period (days)Log-normal (mean: 5.2, SD: 0.1)Log-normal (mean: 5.2, SD: 0.1)Log-normal (mean: 5.2, SD: 0.1)Log-normal (mean: 5.2, SD: 0.1)Log-normal (mean: 5.2, SD: 0.1)(13)
Asymptomatic period (days)Gamma (shape: 5, scale: 1)Gamma (shape: 5, scale: 1)Gamma (shape: 5, scale: 1)Gamma (shape: 5, scale: 1)Gamma (shape: 5, scale: 1)Derived from ref. 12
Presymptomatic period (days)Gamma (shape: 1.058, scale: 2.174)Gamma (shape: 1.058, scale: 2.174)Gamma (shape: 1.058, scale: 2.174)Gamma (shape: 1.058, scale: 2.174)Gamma (shape: 1.058, scale: 2.174)Derived from ref. 1
Infectious period from onset of symptoms (days)Gamma (shape: 2.768, scale: 1.1563)Gamma (shape: 2.768, scale: 1.1563)Gamma (shape: 2.768, scale: 1.1563)Gamma (shape: 2.768, scale: 1.1563)Gamma (shape: 2.768, scale: 1.1563)Derived from ref. 14
Proportion of symptomatic cases with mild symptoms0.950.90.850.600.20(2, 3)
Model parameters and their distributions In the base case scenario, individuals are not isolated at any stage of infection. In order to test whether silent transmission is truly a driver of COVID-19 outbreaks, we then modeled symptom-based case isolation in which symptomatic cases were isolated immediately upon symptom onset and would remain isolated until recovery; thus, one can only transmit the disease during the presymptomatic stage. Case isolation was implemented by reducing the number of daily interactions to a maximum of three contacts, in acknowledgment that household or hospital transmission may still occur despite isolation efforts (2, 3). To identify whether outbreak control (defined as <1% cumulative incidence) could be achieved by curtailing silent transmission, we further considered isolation of presymptomatic and asymptomatic infections. We therefore simulated scenarios in which a proportion (in the range 0 to 50%) of presymptomatic and asymptomatic individuals were isolated, in addition to all symptomatic cases. The model was populated with 10,000 individuals reproducing demography for New York City. For both 17.9% and 30.8% as the asymptomatic proportion (5, 6), we calibrated the model to a reproduction number R0 = 2.5 in the absence of control measures (13). Simulations were seeded with an initial infection, and daily incidence of infection was averaged over 500 independent realizations. Model code is available at https://github.com/ABM-Lab/covid19abm.jl.
  13 in total

1.  Projecting demand for critical care beds during COVID-19 outbreaks in Canada.

Authors:  Affan Shoukat; Chad R Wells; Joanne M Langley; Burton H Singer; Alison P Galvani; Seyed M Moghadas
Journal:  CMAJ       Date:  2020-04-08       Impact factor: 8.262

2.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

3.  Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures.

Authors:  Marino Gatto; Enrico Bertuzzo; Lorenzo Mari; Stefano Miccoli; Luca Carraro; Renato Casagrandi; Andrea Rinaldo
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-23       Impact factor: 11.205

4.  Social contacts and mixing patterns relevant to the spread of infectious diseases.

Authors:  Joël Mossong; Niel Hens; Mark Jit; Philippe Beutels; Kari Auranen; Rafael Mikolajczyk; Marco Massari; Stefania Salmaso; Gianpaolo Scalia Tomba; Jacco Wallinga; Janneke Heijne; Malgorzata Sadkowska-Todys; Magdalena Rosinska; W John Edmunds
Journal:  PLoS Med       Date:  2008-03-25       Impact factor: 11.069

5.  Ebola virus disease contact tracing activities, lessons learned and best practices during the Duport Road outbreak in Monrovia, Liberia, November 2015.

Authors:  Caitlin M Wolfe; Esther L Hamblion; Jacqueline Schulte; Parker Williams; Augustine Koryon; Jonathan Enders; Varlee Sanor; Yatta Wapoe; Dash Kwayon; David J Blackley; Anthony S Laney; Emily J Weston; Emily K Dokubo; Gloria Davies-Wayne; Annika Wendland; Valerie T S Daw; Mehboob Badini; Peter Clement; Nuha Mahmoud; Desmond Williams; Alex Gasasira; Tolbert G Nyenswah; Mosoka Fallah
Journal:  PLoS Negl Trop Dis       Date:  2017-06-02

6.  Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing.

Authors:  Luca Ferretti; Chris Wymant; David Bonsall; Christophe Fraser; Michelle Kendall; Lele Zhao; Anel Nurtay; Lucie Abeler-Dörner; Michael Parker
Journal:  Science       Date:  2020-03-31       Impact factor: 47.728

7.  Projecting hospital utilization during the COVID-19 outbreaks in the United States.

Authors:  Seyed M Moghadas; Affan Shoukat; Meagan C Fitzpatrick; Chad R Wells; Pratha Sah; Abhishek Pandey; Jeffrey D Sachs; Zheng Wang; Lauren A Meyers; Burton H Singer; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-03       Impact factor: 11.205

8.  Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2).

Authors:  Ruiyun Li; Sen Pei; Bin Chen; Yimeng Song; Tao Zhang; Wan Yang; Jeffrey Shaman
Journal:  Science       Date:  2020-03-16       Impact factor: 47.728

9.  Serial Interval of COVID-19 among Publicly Reported Confirmed Cases.

Authors:  Zhanwei Du; Xiaoke Xu; Ye Wu; Lin Wang; Benjamin J Cowling; Lauren Ancel Meyers
Journal:  Emerg Infect Dis       Date:  2020-06-17       Impact factor: 6.883

10.  Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19).

Authors:  Hiroshi Nishiura; Tetsuro Kobayashi; Takeshi Miyama; Ayako Suzuki; Sung-Mok Jung; Katsuma Hayashi; Ryo Kinoshita; Yichi Yang; Baoyin Yuan; Andrei R Akhmetzhanov; Natalie M Linton
Journal:  Int J Infect Dis       Date:  2020-03-14       Impact factor: 3.623

View more
  140 in total

1.  Implementation of primary care clinical pharmacy services for adults experiencing homelessness.

Authors:  Shelby Albertson; Taylor Murray; Jessica Triboletti; Lauren Pence; Jasmine Gonzalvo; Ashley Meredith; Todd Walroth; Judy Rodgers; Liza Crane; John Sidle
Journal:  J Am Pharm Assoc (2003)       Date:  2020-11-05

Review 2.  COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection.

Authors:  Kevin Escandón; Angela L Rasmussen; Isaac I Bogoch; Eleanor J Murray; Karina Escandón; Saskia V Popescu; Jason Kindrachuk
Journal:  BMC Infect Dis       Date:  2021-07-27       Impact factor: 3.090

3.  A bulletin from Greece: a health system under the pressure of the second COVID-19 wave.

Authors:  Constantinos Siettos; Cleo Anastassopoulou; Constantinos Tsiamis; Georgia Vrioni; Athanasios Tsakris
Journal:  Pathog Glob Health       Date:  2021-02-03       Impact factor: 2.894

4.  Immune determinants of COVID-19 disease presentation and severity.

Authors:  Petter Brodin
Journal:  Nat Med       Date:  2021-01-13       Impact factor: 53.440

Review 5.  Balancing incomplete COVID-19 evidence and local priorities: risk communication and stakeholder engagement strategies for school re-opening.

Authors:  Anna G Hoover; Wendy Heiger-Bernays; Sweta Ojha; Kelly G Pennell
Journal:  Rev Environ Health       Date:  2020-10-01       Impact factor: 3.458

6.  Estimating asymptomatic, undetected and total cases for the COVID-19 outbreak in Wuhan: a mathematical modeling study.

Authors:  Xi Huo; Jing Chen; Shigui Ruan
Journal:  BMC Infect Dis       Date:  2021-05-25       Impact factor: 3.090

7.  SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?

Authors:  Mohsina Haq; Asif Rehman; Junaid Ahmad; Usman Zafar; Sufyan Ahmed; Mumtaz Ali Khan; Asif Naveed; Hala Rajab; Fawad Muhammad; Wasifa Naushad; Muhammad Aman; Hafeez Ur Rehman; Sajjad Ahmad; Saeed Anwar; Najib Ul Haq
Journal:  Infection       Date:  2021-05-25       Impact factor: 7.455

8.  What Psychological Factors Make Individuals Believe They Are Infected by Coronavirus 2019?

Authors:  Hojjat Daniali; Magne Arve Flaten
Journal:  Front Psychol       Date:  2021-04-22

9.  Rapid disappearance of influenza following the implementation of COVID-19 mitigation measures in Hamilton, Ontario.

Authors:  Kevin Zhang; Avika Misra; Patrick J Kim; Seyed M Moghadas; Joanne M Langley; Marek Smieja
Journal:  Can Commun Dis Rep       Date:  2021-05-07

10.  Infection kinetics of Covid-19 and containment strategy.

Authors:  Amit K Chattopadhyay; Debajyoti Choudhury; Goutam Ghosh; Bidisha Kundu; Sujit Kumar Nath
Journal:  Sci Rep       Date:  2021-06-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.